Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

PHASE3CompletedINTERVENTIONAL
Enrollment

849

Participants

Timeline

Start Date

August 27, 2003

Primary Completion Date

July 29, 2013

Study Completion Date

December 31, 2018

Conditions
Lymphoma
Interventions
BIOLOGICAL

rituximab

Given IV

DRUG

cisplatin

Given IV

DRUG

cytarabine

Given IV

DRUG

dexamethasone

Given IV

DRUG

gemcitabine hydrochloride

Given IV

Trial Locations (27)

5011

The Queen Elizabeth Hospital, Woodville

15232

University of Pittsburgh Cancer Institute, Pittsburgh

45219

University of Cincinnati, Barrett Cancer Centre, Cincinnati

46202

Indiana University Medical Center, Indianapolis

60612

Rush-Presbyterian-St. Luke's Medical Centre, Chicago

07601

Hackensack University Medical Center, Hackensack

T2N 4N2

Tom Baker Cancer Centre, Calgary

T6G 1Z2

Cross Cancer Institute, Edmonton

R3E 0V9

CancerCare Manitoba, Winnipeg

E1C 6Z8

The Moncton Hospital, Moncton

AIB 3V6

Dr. H. Bliss Murphy Cancer Centre, St. John's

B3H 1V7

QEII Health Sciences Center, Halifax

L8V 5C2

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

K7L 5P9

Cancer Centre of Southeastern Ontario at Kingston, Kingston

N6A 4L6

London Regional Cancer Program, London

L5M 2N1

Credit Valley Hospital, Mississauga

P7B 6V4

Thunder Bay Regional Health Science Centre, Thunder Bay

M4N 3M5

Odette Cancer Centre, Toronto

M5B 1W8

St. Michael's Hospital, Toronto

M5G 2M9

Univ. Health Network-Princess Margaret Hospital, Toronto

J4V 2H1

Hopital Charles LeMoyne, Greenfield Park

H2L 4M1

CHUM - Hopital Notre-Dame, Montreal

G1R 2J6

CHUQ-Pavillon Hotel-Dieu de Quebec, Québec

G1S 4L8

CHA-Hopital Du St-Sacrement, Québec

J1H 5N4

Centre hospitalier universitaire de Sherbrooke, Sherbrooke

S4T 7T1

Allan Blair Cancer Centre, Regina

S7N 4H4

Saskatoon Cancer Centre, Saskatoon

Sponsors
All Listed Sponsors
lead

NCIC Clinical Trials Group

NETWORK

NCT00078949 - Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter